According to Pharmarack, unlike the previous two years where October sales for Oral Rehydration Solutions (ORS) is lesser ...

ICICI Securities is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 34500 in its ...

Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

Wegovy, which uses semaglutide to aid weight loss, was introduced in India in June 2024, two months after Mounjaro's debut.

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities.

Now, it’s worth noting Stock Advisor’s total average return is 1,036% — a market-crushing outperformance compared to 191 % ...

Weight loss drugs like Zepbound and Wegovy will become more accessible to millions of Americans after the Trump ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

At a time when insurers are backing away from coverage for weight loss medications, President Trump has offered a lifeline ...